Nu-Med Plus (NUMD) Assets (2011 - 2025)

Nu-Med Plus (NUMD) posted Assets of $7911.0 for Q4 2025, up 56.72% sequentially from $5048.0 in Q3 2025, and down 15.6% YoY from $9373.0 in Q4 2024.

Nu-Med Plus (NUMD) Assets (2011 - 2025) Analysis & Trends

Nu-Med Plus has reported Assets for 15 years, with the latest figure at $7911.0 in Q4 2025.

Quarterly Assets fell 15.6% year-over-year to $7911.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $7911.0 (down 15.6% YoY) and the FY2025 annual result came in at $7911.0, down 15.6% from the prior year.
Assets rose to $7911.0 in Q4 2025 per NUMD's latest filing, from $5048.0 in the prior quarter.
Over five years, Assets peaked at $285013.0 in Q1 2021 and troughed at $3168.0 in Q3 2022.
A 5-year average of $36600.4 and a median of $10207.0 in 2024 frame the typical range for Assets.
The sharpest annual moves came in 2022 and 2023: Assets sank 97.22% in 2022, then jumped 645.26% in 2023.
Over 5 years, Assets stood at $22163.0 in 2021, then soared by 258.91% to $79545.0 in 2022, then tumbled by 83.08% to $13456.0 in 2023, then tumbled by 30.34% to $9373.0 in 2024, then dropped by 15.6% to $7911.0 in 2025.
According to Business Quant data, Assets over the past three periods registered $7911.0, $5048.0, and $8163.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Assets (Qtr)
1	Abbott Laboratories	198.95 Bn	193.34 Bn	7.27 Bn	109.22 Bn
2	Stryker	127.40 Bn	123.93 Bn	4.50 Bn	47.93 Bn
3	Medtronic	118.77 Bn	109.55 Bn	6.41 Bn	93.03 Bn
4	Boston Scientific	73.24 Bn	72.71 Bn	3.85 Bn	45.22 Bn
5	Edwards Lifesciences	51.95 Bn	47.70 Bn	1.35 Bn	13.87 Bn
6	Dexcom	34.39 Bn	32.44 Bn	830.00 Mn	6.46 Bn
7	GE HealthCare Technologies	33.87 Bn	31.76 Bn	2.18 Bn	37.25 Bn
8	Koninklijke Philips	26.34 Bn	23.02 Bn	4.55 Bn	31.04 Bn
9	Steris	23.04 Bn	22.56 Bn	684.20 Mn	10.74 Bn
10	Nu-Med Plus	2.03 Mn	2.02 Mn	-	12,909.00

Download Data